Coherus BioSciences (NASDAQ:CHRS) Research Coverage Started at Robert W. Baird
Robert W. Baird began coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research note published on Friday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $11.00 price target on the biotechnology company’s stock. CHRS has been the subject of a number of other research reports. Truist Financial reaffirmed […]
More Stories
Murder in a Small Town Season 3 Is Releasing Soon on Netflix
Murder in a Small Town Season 3 is coming back with an-all-new drama and suspenseful storyline for its viewers. The...
Netflix’s Fauda Season 5: Release Date, Cast Members, Plot, and Episodes
Fauda season 5 is coming to Netflix soon! Your years of waiting are finally over. Are you also one of...
How to Cancel Hulu Subscriptions? A Complete Guide For Beginners
Worried about your money being deducted? Do you also have a subscription and now don’t know how to cancel your...
Dolly Parton, queen of country music, dies at 80
By Reuters Aug 25 (Reuters) – Dolly Parton was around six when she wrote her first song: “Little Tiny Tasseltop,”...
Canada’s Dollar-for-Dollar Tariff Response Exposes a Trade Relationship America Should Have Reexamined Decades Ago
By Stephen Zogopoulos, USNN World News Canada has now formally answered Washington’s latest tariffs with what it calls a “dollar-for-dollar,...
South Carolinians Go to Polls for Key Republican Senate Primary
By Joseph Lord CHARLESTON, S.C.—South Carolina voters will head to the polls today to make their pick in a runoff...